Replies to post #89398 on Biotech Values

[DewDiligence]

FDA places clinical hold on Ipsen’s Factor IX program due to detectable antibodies against CHO proteins used in manufacturing:

http://finance.yahoo.com/news/ipsen-partner-inspiration-biopharmaceuticals-announces-050000739.html

Factor IX the lead program among several hemophilia-related projects pursuant to a 2010 collaboration between Ipsen and Inspiration Biopharma (#msg-45759144).